Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07233655 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Active, Not Recruiting Primary completion moved earlier from Jul 2026 to Apr 21, 2026 · Site details revisedv4 Show 2 more changesShow less
    • Primary completion moved earlier from Jul 2026 to Apr 21, 2026
    • Site details revised
  2. Eligibility criteria expanded, about 29 wordsv3 See this version in full on ClinicalTrials.gov ↗
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2025 to Jan 19, 2026 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2025 to Jan 19, 2026
    • Site details revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
Trial Details
NCT Number NCT07233655
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Moderate to Severe Active Rheumatoid Arthritis
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov